-+ 0.00%
-+ 0.00%
-+ 0.00%

On August 5, CSPC announced on the Hong Kong Stock Exchange that on August 5, 2026, the Group received a milestone payment of 10 million US dollars from AstraZeneca to exercise the right to authorize one of the PCC projects in accordance with the terms of the agreement, indicating that related R&D work under the agreement is progressing steadily according to the plan. Earlier announcements revealed that the Group agreed to discover pre-clinical drug candidates with potential treatment potential for multi-indication diseases for multiple targets selected by AstraZeneca, including a preclinical small molecule oral therapy for immune diseases.

Zhitongcaijing·08/05/2026 13:17:06
Listen to the news
On August 5, CSPC announced on the Hong Kong Stock Exchange that on August 5, 2026, the Group received a milestone payment of 10 million US dollars from AstraZeneca to exercise the right to authorize one of the PCC projects in accordance with the terms of the agreement, indicating that related R&D work under the agreement is progressing steadily according to the plan. Earlier announcements revealed that the Group agreed to discover pre-clinical drug candidates with potential treatment potential for multi-indication diseases for multiple targets selected by AstraZeneca, including a preclinical small molecule oral therapy for immune diseases.